NCT02349451View on ClinicalTrials.gov

A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

April 28, 2015

Primary Completion Date

July 4, 2016

Study Completion Date

July 4, 2016

Conditions
Psoriatic Arthritis
Interventions
BIOLOGICAL

adalimumab

BIOLOGICAL

ABT-122

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY